Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including ...
Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation TechnologyExpert consensus predicts integration of CTC testing into ...
ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.
Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management ...
Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...
Biodesix, Inc has expanded its long-standing collaboration with Bio-Rad Laboratories to co-develop and clinically validate ...
Expert consensus predicts integration of CTC testing into routine clinical practice within 5 years 2. CTCs provide distinct and impactful information that is not captured by circulating tumour DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback